Introduction: LixiLan-O-AP (NCT03798054) showed greater HbA1c improvement with iGlarLixi vs. iGlar or Lixi in Asian Pacific adults with type 2 diabetes (T2D) . This pre-defined analysis assessed iGlarLixi efficacy by HbA1c levels at screening.

Methods: Adults (N=878) with suboptimally controlled T2D (HbA1c of 7.5-% or 7-% depending on background oral antihyperglycemic drug [OAD] use) on metformin ± a second OAD were randomized 2:2:1 to iGlarLixi, iGlar or Lixi for 24 weeks. Three screening HbA1c subgroups were defined: <8, 8-<9, ≥9 %.

Results: At Week 24, in all HbA1c subgroups, iGlarLixi was associated with greater HbA1c reductions vs. iGlar or Lixi and reached mean HbA1c levels <7 %. iGlarLixi also showed greater 2-h postprandial glucose reductions, and a higher proportion of participants reaching HbA1c <7 % and HbA1c <7 % without weight gain, vs. iGlar or Lixi (Table) . Incidence and rates of documented hypoglycemia ≤70 mg/dL (≤3.9 mmol/L) were similar between iGlarLixi and iGlar in the 8-<9 % and ≥9 % subgroups but were slightly higher with iGlarLixi vs. iGlar in the <8 % subgroup.

Conclusions: Regardless of HbA 1c level at screening, iGlarLixi demonstrated better glycemic control vs. iGlar or Lixi, with over 75% of participants achieving the recommended target HbA 1c (<7 %) with iGlarLixi, even those with HbA1c ≥9 % at screening.


Y. He: None. W. Yang: Other Relationship; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Mer, Merck Sharp & Dohme Corp., Novo Nordisk, Sanofi-Aventis Deutschland GmbH, Servier Laboratories. M. Liu: None. J. Xiao: None. S. Gu: Employee; Sanofi China. L. Chen: None. E. Souhami: Employee; Sanofi. Stock/Shareholder; Sanofi.


Funding: Sanofi

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at